Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain
Professor of Breast Cancer Medicine
Department of Medicine
Royal Marsden Hospital
London, United Kingdom
Associate Professor of Medicine
Harvard Medical School
Susan F. Smith Center for Women's Cancer
Director of Clinical Trials, Breast Oncology
Director of Breast Immunotherapy Clinical Research
Breast Oncology Program
Dana-Farber Cancer Institute
This program has been made available online.
In this commentary from Clinical Care Options (CCO), experts look ahead to key studies being reported at SABCS 2021 and highlight what data they are most excited to see
Laura M. Spring, MD, discusses the use of abemaciclib in patients with HR-positive, HER2-negative, node-positive early breast cancer, from Clinical Care Options (CCO)
Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors
Expert podcast on second-generation TRK inhibitors with Dr. George Demetri and Dr. Alexander Drilon, from Clinical Care Options (CCO)